PUBLISHER: Renub Research | PRODUCT CODE: 1484144
PUBLISHER: Renub Research | PRODUCT CODE: 1484144
China Biopsy Market Report by Products, Imaging Technology, End-User, and Company Analysis 2024-2032
China Biopsy Device Market share is expected to be almost US$ 1,059.41 Million by 2032 compared to US$ 574.31 Million in 2023. Renub Research stated that the industry is foreseen to increase at a CAGR of 7.04% from 2024 to 2032.
A biopsy is a process to terminate a portion of tissue or a sample of cells from the body to be tried in a laboratory. People may undergo a biopsy if they are experiencing certain signs and symptoms or if the health care provider has identified an area of concern. A biopsy can determine whether an individual has cancer or another condition. Imaging tests, such as CT scans or MRIs, help detect masses or irregular tissue, but they alone can't tell the difference between cancerous cells and cells that aren't cancerous. For most cancers, the only way to make a diagnosis is to conduct a biopsy to gather cells for a more intimate assessment.
China Biopsy Device Market Growth Factors
China's population demographics, disease incidence, and prevalence are the key factors driving the growth of the biopsy device market in China.
According to figures from the National Bureau of Statistics (NBS), 1.40967 billion people lived in China in 2023. With 9.02 million births in 2023, the birth rate per thousand people was 6.39.
The NIH publications state that China saw about 4,824,700 new cases of cancer in 2022 (2,533,900 male cases and 2,290,800 female cases).
It also notes that 57.4% of all new cases of cancer were caused by the top five malignancies, which are lung cancer (1,060,600), colorectal cancer (517,100), thyroid cancer (466 100), liver cancer (367,700), and female breast cancer (357,200).
In China, it is projected that 2,574,200 people will lose their lives to cancer in 2022 (1,629,300 men and 944,900 women).
The China biopsy device market is anticipated to be driven by several government and non-government organizations' cancer screening programs and initiatives.
Duke University's project intends to conduct several research studies to identify and develop efficient interventions and policies to help close the disparity in cancer rates in China. The project will also create several cancer advocacy resources to increase awareness of cancer disparities among broader global populations.
To achieve a 46.6 percent overall five-year survival rate among cancer patients by 2030, the Chinese government has released an eight-year action plan for cancer prevention and treatment. The plan states that by 2030, the burden of treating these diseases will be under control, the increasing trend in cancer incidence and death will be moderated, and the capacity for cancer screening, early diagnosis, and treatment will be significantly improved.
The federal Chinese government funds four national cancer screening programs (NCSPs), which serve as the cornerstone of cancer screening in China. China presently includes eight cancer types in its NCSPs: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal.
China Biopsy Device Industry News
The China biopsy device market is segmented into various companies, such as Bio-Rad Laboratories, Exact Sciences (Genomic Health), Becton, Dickinson and Company, Roche Diagnostics, Thermo Fisher Scientific Inc., Qiagen, Biocept, Quest Diagnostics Inc., and NeoGenomics Laboratories.
In October 2023 - LUMINELLE announced its decision to expand its global footprint by receiving a patent for its LUMINELLE Bx (Biopsy) System from the China National Intellectual Property Administration.
In September 2023 - Baird Medical Investment Holdings Limited reported that Jiangsu Medical Products Administration, the pharmaceuticals regulatory authority for Jiangsu Province in China, has approved its Single-Use Sterile Biopsy Needle ("SSBN") through its subsidiary Nanjing Changcheng Medical Equipment Co., Ltd. The device, approved on August 30, 2023, and has registration number 20232141234, is used for biopsies of tumors in superficial tissues close to the skin's surface, such as the thyroid, lymph nodes, and breasts.
In July 2023 - The cfDNA liver cancer detection test from Helio Genomics' sister company, Laboratory for Advanced Medicine and Health Group (LAMH), received approval from China's National Medical Products Administration (NMPA). It is stated to be a first in the field of blood-based cancer detection-the first liquid biopsy test authorized by NMPA for liver cancer.
Products - Market is broken up into 4 viewpoints:
1. Needle Based Biopsy Devices
2. Biopsy Forceps
3. Localization Wire
4. Others Products
Imaging Technology - Market is broken up into 5 viewpoints:
1. CT scan
2. Stereotactic Guided
3. Ultrasound Guided
4. MRI Guided
5. Others
End-User - Market is broken up into 3 viewpoints:
1. Hospital and Clinics
2. Diagnostics Laboratories
3. Other
All companies have been covered from 3 viewpoints:
- Overview
- Recent Development
- Revenue
Company Analysis:
1. Bio-Rad Laboratories
2. Exact Sciences (Genomic Health)
3. Becton, Dickinson and Company
4. Roche Diagnostics
5. Thermo Fisher Scientific Inc.
6. Qiagen
7. Biocept
8. Quest Diagnostics Inc.
9. NeoGenomics Laboratories
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
5. China Biopsy Device Market
6. Market Share - China Biopsy Device Analysis
- 6.1 By Products
- 6.2 By Imaging Technology
- 6.3 By End User
7. Product - China Biopsy Device Market
- 7.1 Needle Based Biopsy Devices
- 7.2 Biopsy Forceps
- 7.3 Localization Wire
- 7.4 Others Products
8. Imaging Technology - China Biopsy Device Market
- 8.1 Ct scan
- 8.2 Stereotactic Guided
- 8.3 Ultrasound Guided
- 8.4 MRI Guided
- 8.5 Others
9. End User - China Biopsy Device Market
- 9.1 Hospital and Clinics
- 9.2 Diagnostics Laboratories
- 9.3 Other
10. Porter's Five Forces Analysis - China Biopsy Device Market
- 10.1 Bargaining Power of Buyers
- 10.2 Bargaining Power of Suppliers
- 10.3 Degree of Competition
- 10.4 Threat of New Entrants
- 10.5 Threat of Substitutes
11. SWOT Analysis - China Biopsy Device Market
- 11.1 Strength
- 11.2 Weakness
- 11.3 Opportunity
- 11.4 Threats
12. Key Players Analysis
- 12.1 Bio-Rad Laboratories
- 12.1.1 Overview
- 12.1.2 Key Persons
- 12.1.3 Product Analysis
- 12.1.4 Recent Developments
- 12.1.5 Revenue
- 12.2 Exact Sciences (Genomic Health)
- 12.2.1 Overview
- 12.2.2 Key Persons
- 12.2.3 Product Analysis
- 12.2.4 Recent Developments
- 12.2.5 Revenue
- 12.3 Becton, Dickinson and Company
- 12.3.1 Overview
- 12.3.2 Key Persons
- 12.3.3 Product Analysis
- 12.3.4 Recent Developments
- 12.3.5 Revenue
- 12.4 Roche Diagnostics
- 12.4.1 Overview
- 12.4.2 Key Persons
- 12.4.3 Product Analysis
- 12.4.4 Recent Developments
- 12.4.5 Revenue
- 12.5 Thermo Fisher Scientific Inc.
- 12.5.1 Overview
- 12.5.2 Key Persons
- 12.5.3 Product Analysis
- 12.5.4 Recent Developments
- 12.5.5 Revenue
- 12.6 Qiagen
- 12.6.1 Overview
- 12.6.2 Key Persons
- 12.6.3 Product Analysis
- 12.6.4 Recent Developments
- 12.6.5 Revenue
- 12.7 Biocept
- 12.7.1 Overview
- 12.7.2 Key Persons
- 12.7.3 Product Analysis
- 12.7.4 Recent Developments
- 12.7.5 Revenue
- 12.8 Quest Diagnostics Inc.
- 12.8.1 Overview
- 12.8.2 Key Persons
- 12.8.3 Product Analysis
- 12.8.4 Recent Developments
- 12.8.5 Revenue
- 12.9 NeoGenomics Laboratories
- 12.9.1 Overview
- 12.9.2 Key Persons
- 12.9.3 Product Analysis
- 12.9.4 Recent Developments
- 12.9.5 Revenue
List of Figures
- Figure-01: China - Biopsy Device Market (Billion US$), 2019 - 2023
- Figure-02: China - Forecast for Biopsy Device Market (Billion US$), 2024 - 2032
- Figure-03: Product - Needle Based Biopsy Devices Market (Million US$), 2019 - 2023
- Figure-04: Product - Forecast for Needle Based Biopsy Devices Market (Million US$), 2024 - 2032
- Figure-05: Product - Biopsy Forceps Market (Million US$), 2019 - 2023
- Figure-06: Product - Forecast for Biopsy Forceps Market (Million US$), 2024 - 2032
- Figure-07: Product - Localization Wire Market (Million US$), 2019 - 2023
- Figure-08: Product - Forecast for Localization Wire Market (Million US$), 2024 - 2032
- Figure-09: Product - Others Products Market (Million US$), 2019 - 2023
- Figure-10: Product - Forecast for Others Products Market (Million US$), 2024 - 2032
- Figure-11: Imaging Technology - Ct scan Market (Million US$), 2019 - 2023
- Figure-12: Imaging Technology - Forecast for Ct scan Market (Million US$), 2024 - 2032
- Figure-13: Imaging Technology - Stereotactic Guided Market (Million US$), 2019 - 2023
- Figure-14: Imaging Technology - Forecast for Stereotactic Guided Market (Million US$), 2024 - 2032
- Figure-15: Imaging Technology - Ultrasound Guided Market (Million US$), 2019 - 2023
- Figure-16: Imaging Technology - Forecast for Ultrasound Guided Market (Million US$), 2024 - 2032
- Figure-17: Imaging Technology - MRI Guided Market (Million US$), 2019 - 2023
- Figure-18: Imaging Technology - Forecast for MRI Guided Market (Million US$), 2024 - 2032
- Figure-19: Imaging Technology - Others Market (Million US$), 2019 - 2023
- Figure-20: Imaging Technology - Forecast for Others Market (Million US$), 2024 - 2032
- Figure-21: End User - Hospital and Clinics Market (Million US$), 2019 - 2023
- Figure-22: End User - Forecast for Hospital and Clinics Market (Million US$), 2024 - 2032
- Figure-23: End User - Diagnostics Laboratories Market (Million US$), 2019 - 2023
- Figure-24: End User - Forecast for Diagnostics Laboratories Market (Million US$), 2024 - 2032
- Figure-25: End User - Other Market (Million US$), 2019 - 2023
- Figure-26: End User - Forecast for Other Market (Million US$), 2024 - 2032
- Figure-27: Bio-Rad Laboratories - Global Revenue (Million US$), 2019 - 2023
- Figure-28: Bio-Rad Laboratories - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-29: Exact Sciences (Genomic Health) - Global Revenue (Million US$), 2019 - 2023
- Figure-30: Exact Sciences (Genomic Health) - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-31: Becton, Dickinson and Company - Global Revenue (Million US$), 2019 - 2023
- Figure-32: Becton, Dickinson and Company - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-33: Roche Diagnostics - Global Revenue (Million US$), 2019 - 2023
- Figure-34: Roche Diagnostics - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-35: Thermo Fisher Scientific Inc. - Global Revenue (Million US$), 2019 - 2023
- Figure-36: Thermo Fisher Scientific Inc. - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-37: Qiagen - Global Revenue (Million US$), 2019 - 2023
- Figure-38: Qiagen - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-39: Biocept - Global Revenue (Million US$), 2019 - 2023
- Figure-40: Biocept - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-41: Quest Diagnostics Inc. - Global Revenue (Million US$), 2019 - 2023
- Figure-42: Quest Diagnostics Inc. - Forecast for Global Revenue (Million US$), 2024 - 2032
- Figure-43: NeoGenomics Laboratories - Global Revenue (Million US$), 2019 - 2023
- Figure-44: NeoGenomics Laboratories - Forecast for Global Revenue (Million US$), 2024 - 2032
List of Tables
- Table-01: China - Biopsy Device Market Share by Product (Percent), 2019 - 2023
- Table-02: China - Forecast for Biopsy Device Market Share by Product (Percent), 2024 - 2032
- Table-03: China - Biopsy Device Market Share by Imaging Technology (Percent), 2019 - 2023
- Table-04: China - Forecast for Biopsy Device Market Share by Imaging Technology (Percent), 2024 - 2032
- Table-05: China - Biopsy Device Market Share by End User (Percent), 2019 - 2023
- Table-06: China - Forecast for Biopsy Device Market Share by End User (Percent), 2024 - 2032
